ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Emre Yekedüz ◽  
Elif Berna Köksoy ◽  
Hakan Akbulut ◽  
Yüksel Ürün ◽  
Güngör Utkan
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Circulating Tumor Dna ◽  
Random Effects Model ◽  
Inverse Variance ◽  
Increased Risk ◽  
Significant Step ◽  
Tumor Dna

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on March 31, 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.

scholarly journals Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis

2017 ◽  
Vol Volume 10 ◽  
pp. 945-953 ◽  
Author(s):  
Yi-xin Hao ◽  
Qiang Fu ◽  
Yan-Yan Guo ◽  
Ming Ye ◽  
Hui-Xia Zhao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Gene Mutations ◽  
Circulating Tumor Dna ◽  
Kras Gene ◽  
Colorectal Cancer Patients ◽  
Tumor Dna

Abstract 3096: Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients

2020 ◽  
Author(s):  
Carmen Rubio Alarcón ◽  
Dave E. van der Kruijssen ◽  
Lana Meiqari ◽  
Linda J. Bosch ◽  
John K. Simmons ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Prognostic Biomarker ◽  
Circulating Tumor Dna ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Tumor Dna

scholarly journals Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Ya Gao ◽  
Ming Liu ◽  
Shuzhen Shi ◽  
Yamin Chen ◽  
Yue Sun ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Sensitivity Analyses ◽  
Severe Illness ◽  
Risk Of Death ◽  
Inverse Variance ◽  
Pooled Prevalence ◽  
Increased Risk ◽  
Meta Analyses ◽  
Prevalence Of Cancer

AbstractBackgroundCancer patients are considered a highly vulnerable population in the COVID-19 epidemic, but the relationship between cancer and the severity and mortality of patients with COVID-19 remains unclear. This study aimed to explore the prevalence of cancer in patients with COVID-19 and to examine whether cancer patients with COVID-19 may be at an increased risk of severe illness and mortality.MethodsA comprehensive electronic search in seven databases was performed, to identified studies reporting the prevalence of cancer in COVID-19 patients, or providing data of cancer between patients with severe or non-severe illness or between non-survivors and survivors. Meta-analyses were performed to estimate the pooled prevalence and odds risk (OR) using the inverse variance method with the random-effects model.ResultsThirty-four studies with 8080 patients were included. The pooled prevalence of cancer in patients with COVID-19 was 2.0% (95% CI: 2.0% to 3.0%). The prevalence in Italy (5.0%), France (6.0%), and Korea (4.0%) were higher than that in China (2.0%). Cancer was associated with a 2.84-fold significantly increased risk of severe illness (OR = 2.84, 95%CI: 1.75 to 4.62, P < 0.001) and a 2.60-fold increased risk of death (OR = 2.60, 95%CI: 1.28 to 5.26, P = 0.008) in patients with COVID-19. Sensitivity analyses showed that the results were stable after excluding studies with a sample size of less than 100.ConclusionsCancer patients have an increased risk of COVID-19 and cancer was associated with a significantly increased risk of severity and mortality of patients with COVID-19.

Abstract CT251: MEDOCC-CrEATE trial in progress: effectiveness of adjuvant chemotherapy in stage II colon cancer patients with positive circulating tumor DNA

2021 ◽  
Author(s):  
Suzanna J. Schraa ◽  
Karlijn L. Van Rooijen ◽  
Dave E. Van Der Kruijssen ◽  
Carmen Rubio Alarcón ◽  
Jillian Phallen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Circulating Tumor Dna ◽  
Stage Ii ◽  
Stage Ii Colon Cancer ◽  
Tumor Dna

scholarly journals P-65 Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review

2021 ◽  
Vol 32 ◽  
pp. S118-S119
Author(s):  
J. Tandiono ◽  
E. Marcella ◽  
S. Chen ◽  
C. Jonatan ◽  
R. Heriyanto ◽  
...  
Keyword(s):  
Systematic Review ◽  
Colon Cancer ◽  
Prognostic Factor ◽  
Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document